Role of the endogenous signalling regulator Similar Expression to FGF (Sef) in growth factor signalling in prostate cancer

前列腺癌是英国最常见的男性恶性肿瘤（每年新发35000例）。尽管进行了包括手术在内的治疗，但许多患者仍会患上一种致命的疾病，称为去势抵抗性前列腺癌。这个过程部分是由称为生长因子的分子驱动的。我们正在研究一种名为Sef的基因，它是一种强大的生长因子天然抑制剂。我们的目的是测试增加前列腺肿瘤中的Sef是否可以增强旨在阻断生长因子的治疗。如果成功的话，这将为治疗男性致命的前列腺癌提供一种新的方法。

Targeting growth factors in prostate cancer Prostate cancer is the commonest male malignancy in the UK (35000 new cases/year). Despite treatment including surgery, many patients will develop a lethal form of disease known as castration resistant prostate cancer. This process is driven in part by molecules called growth factors. We are investigating a gene called Sef which functions as a strong natural inhibitor of growth factors. Our aim is to test if increasing Sef in prostate tumours can enhance treatment designed to block growth factors. If successful, this will offer a new way to treat men with otherwise fatal prostate cancer.